BIODLINK-B (01875) released its annual performance, with a profit of 748 million yuan. The strategic transformation into a CDMO has achieved significant results.

BIODLINK-B (01875) released its performance for the year ending December 31, 2025. The group's total revenue was 748 million yuan (same unit), a decrease of 31.93% compared to the previous year. Research and development expenses were 85.675 million yuan, an increase of 8.02% compared to the previous year. The loss attributable to equity holders of the company was approximately 100 million yuan, with a loss of 0.14 yuan per share. The announcement stated that product sales revenue was 488 million yuan, a decrease of 44% compared to the previous year, mainly due to increased market competition. CDMO business revenue was 235 million yuan, an increase of 13% compared to the previous year. Self-developed products made an important breakthrough in international layout: The self-developed product Parkinson (bevacizumab injection) was successfully approved for market in 5 countries (including Nigeria, Pakistan, Colombia, Indonesia, Bolivia), and completed its first overseas orders to Colombia, Indonesia, and Nigeria, achieving a key transition from "registration approval" to "commercial sales". The strategic transformation of CDMO has yielded significant results, becoming a stable "ballast" for the company: Multiple new technology platforms have been introduced, strengthening front-end traffic, and significantly increasing early-stage projects. 60 new projects were added throughout the year, totaling 213 projects, with ADC-related projects accounting for 68%. One PreBLA (Pre-Biologics License Application) project was successfully obtained during the year, with a total of 8 in hand, securing potential future income. The value of signed but unfinished orders reached 308 million yuan, an increase of 61% compared to the previous year. The successful empowerment of the world's first EGFRADC drug, Leap Bioscience's "Meiyouheng," gaining market approval in China, has set a milestone in the industry. This fully demonstrates Dongyao Pharmaceuticals' strong capabilities in converting cutting-edge science into reliable products in the field of high-barrier complex drugs such as ADCs, and has established solid industry competitive barriers. The company's high-standard quality management system has been widely recognized in the domestic and international industry, having passed numerous production site inspections by drug regulatory authorities, GMP compliance checks in multiple countries, as well as GMP inspections by customers and third-party consulting firms. In 2025, the company underwent a total of 37 GMP inspections/audits with a 100% pass rate, including 6 inspections by the Chinese drug regulatory authority and 4 EU QP audits, obtaining GMP certificates from countries such as Brazil, Argentina, and Thailand, as well as a registration approval letter from Syria. Additionally, the company has actively cooperated with customers to complete overseas inspections by multinational pharmaceutical companies and organizations, successfully obtaining authorization and high recognition.